Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

14 questions · 14 findings · 1 reviews · Heart

No studies found 9 · 64.3%GRADE not reported 0 · 0%Very low 4 · 28.6%Low 1 · 7.1%Moderate 0 · 0%High 0 · 0%

Lipopeptide antibiotic (daptomycin) vs aminoglycoside (low‐dose gentamicin) plus anti‐staphylococcal penicillin (nafcillin, oxacillin or flucloxacillin) or glycopeptide antibiotic (vancomycin)

Adverse events1 · people with endocarditis caused by Staphylococcus aureus

The review found no eligible studies for this question.

1 finding from 1 review

Lipopeptide antibiotic (daptomycin) vs aminoglycoside (low‐dose gentamicin) plus anti‐staphylococcal penicillin (nafcillin, oxacillin or flucloxacillin) or glycopeptide antibiotic (vancomycin)

Congestive heart failure · people with endocarditis caused by Staphylococcus aureus

The review found no eligible studies for this question.

1 finding from 1 review

Lipopeptide antibiotic (daptomycin) vs aminoglycoside (low‐dose gentamicin) plus anti‐staphylococcal penicillin (nafcillin, oxacillin or flucloxacillin) or glycopeptide antibiotic (vancomycin)

Septic embolism1 · people with endocarditis caused by Staphylococcus aureus

The review found no eligible studies for this question.

1 finding from 1 review

Lipopeptide antibiotic (daptomycin) vs aminoglycoside (low‐dose gentamicin) plus anti‐staphylococcal penicillin (nafcillin, oxacillin or flucloxacillin) or glycopeptide antibiotic (vancomycin)

Need for cardiac surgical interventions · people with endocarditis caused by Staphylococcus aureus

The review found no eligible studies for this question.

1 finding from 1 review

Lipopeptide antibiotic (daptomycin) vs aminoglycoside (low‐dose gentamicin) plus anti‐staphylococcal penicillin (nafcillin, oxacillin or flucloxacillin) or glycopeptide antibiotic (vancomycin)

Uncontrolled infection1 · people with endocarditis caused by Staphylococcus aureus

The review found no eligible studies for this question.

1 finding from 1 review

Beta‐lactam (ceftriaxone) plus aminoglycoside (gentamicin) vs beta‐lactam (ceftriaxone)

All‐cause mortality during hospital stay and all‐cause mortality at 1 year · people with infective endocarditis due to penicillin‐susceptible Streptococci

The review found no eligible studies for this question.

1 finding from 1 review

Beta‐lactam (ceftriaxone) plus aminoglycoside (gentamicin) vs beta‐lactam (ceftriaxone)

Cure · people with infective endocarditis due to penicillin‐susceptible Streptococci

Beta‐lactam (ceftriaxone) plus aminoglycoside (gentamicin) showed no clear difference in cure compared with beta‐lactam (ceftriaxone) (low certainty).

1 finding from 1 review

Beta‐lactam (ceftriaxone) plus aminoglycoside (gentamicin) vs beta‐lactam (ceftriaxone)

Adverse events · people with infective endocarditis due to penicillin‐susceptible Streptococci

It is very uncertain whether beta‐lactam (ceftriaxone) plus aminoglycoside (gentamicin) changes adverse events compared with beta‐lactam (ceftriaxone) (very low certainty).

1 finding from 1 review

Beta‐lactam (ceftriaxone) plus aminoglycoside (gentamicin) vs beta‐lactam (ceftriaxone)

Need for cardiac surgical interventions · people with infective endocarditis due to penicillin‐susceptible Streptococci

It is very uncertain whether beta‐lactam (ceftriaxone) plus aminoglycoside (gentamicin) changes need for cardiac surgical interventions compared with beta‐lactam (ceftriaxone) (very low certainty).

1 finding from 1 review

Beta‐lactam (ceftriaxone) plus aminoglycoside (gentamicin) vs beta‐lactam (ceftriaxone)

Uncontrolled infection · people with infective endocarditis due to penicillin‐susceptible Streptococci

It is very uncertain whether beta‐lactam (ceftriaxone) plus aminoglycoside (gentamicin) changes uncontrolled infection compared with beta‐lactam (ceftriaxone) (very low certainty).

1 finding from 1 review

Lipopeptide antibiotic (daptomycin) vs aminoglycoside (low‐dose gentamicin) plus anti‐staphylococcal penicillin (nafcillin, oxacillin or flucloxacillin) or glycopeptide antibiotic (vancomycin)

All‐cause mortality during hospital stay and all‐cause mortality at 1 year · people with endocarditis caused by Staphylococcus aureus

The review found no eligible studies for this question.

1 finding from 1 review

Lipopeptide antibiotic (daptomycin) vs aminoglycoside (low‐dose gentamicin) plus anti‐staphylococcal penicillin (nafcillin, oxacillin or flucloxacillin) or glycopeptide antibiotic (vancomycin)

Cure · people with endocarditis caused by Staphylococcus aureus

It is very uncertain whether lipopeptide antibiotic (daptomycin) changes cure compared with aminoglycoside (low‐dose gentamicin) plus antistaphylococcal… (very low certainty).

1 finding from 1 review